Biologic Comparison of Inhaled Insulin Formulations: ExuberaTMand Novel Spray-Dried Engineered Particles of Dextran-10

Ageing International

Volumn 15, Issue 6, 2014, Pages 1545-1550

  Kuehl, Philip J ^a   Cherrington, Alan ^c   Dobry, Dan E ^b   Edgerton, Dale ^c   Friesen, Dwayne T ^b   Hobbs, Charles ^a   Leach, Chet L ^a   Murri, Brice ^b   Neal, Doss ^c   Lyon, David K ^b   Vodak, David T ^b   Reed, Matthew D ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b Bend Research Incorporated   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

dextran; inhalation; insulin; pharmacokinetics; spray drying

Indexed keywords

AEROSOL; ANTIDIABETIC AGENT; DEXTRAN; DRUG CARRIER; GLUCOSE BLOOD LEVEL; INSULIN; POWDER; RECOMBINANT HUMAN INSULIN;

AEROSOL; ANIMAL; AREA UNDER THE CURVE; BLOOD; CHEMISTRY; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DOG; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; INHALATIONAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLIC CLEARANCE RATE; METABOLISM; PARTICLE SIZE; PHARMACEUTICS; POWDER; PROCEDURES;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; AREA UNDER CURVE; BLOOD GLUCOSE; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DEXTRANS; DOGS; DRUG CARRIERS; FEMALE; HYPOGLYCEMIC AGENTS; INSULIN; METABOLIC CLEARANCE RATE; PARTICLE SIZE; POWDERS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84912076140     PISSN: 01635158     EISSN: 1936606X     Source Type: Journal    
DOI: 10.1208/s12249-014-0181-0     Document Type: Article

References (22)

1. Hickey AJ. Back to the future: inhaled drug products. J Pharm Sci. 2013;102(4):1165–72.
2. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2004;1(4):338–44.
3. Grant M, Leone-Bay A. Peptide therapeutics: it’s all in the delivery. Ther Deliv. 2012;3(8):981–96.
4. Hacha J, Tomlinson K, Maertens L, Paulissen G, Rocks N, Foidart JM, et al. Nebulized anti-IL-13 monoclonal antibody Fab’ fragment reduces allergen-induced asthma. Am J Respir Cell Mol Biol. 2012;47(5):709–17.
5. Tomkinson A, Tepper J, Morton M, Bowden A, Stevens L, Harris P, et al. Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma. Allergy. 2010;65(1):69–77.
6. Grasmeijer N, Stankovic M, de Waard H, Frijlink HW, Hinrichs WL. Unraveling protein stabilization mechanisms: vitrification and water replacement in a glass transition temperature controlled system. Biochim Biophys Acta. 2013;1834(4):763–9.
7. Gellar DE, Weers J, Heurerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology. J Aerosol Med Pulm Drug Deliv. 2011;24(4):175–82.
8. Chi P, Kwok L, Chan H-K. Pulmonary delivery of peptides and proteins. In: Van der Walle C, editor. Protein and peptide delivery. 2011.
9. Code of Federal Regulations. Title 21-Food and drugs, chapter 1—food and drug administration department of health and human services. Subchapter E, Animal drugs, feeds, and related products. Part 582, Substances generally recognized as safe. Subpart B, General Purpose food additives. Sec. 582.1275, Dextrans. 2013 Revised. Accessed Jan 2014.
10. Vodak DT, Dobry DE, Kuehl PJ, Barrett EG, Rudolph K, McDonald JD, et al. Assessment of lung function in a ragweed challenge dog model after inhalation of engineered particle formulation of albuterol sulphate. Proc Resp Drug Deliv. 2010;2:431–4.
11. Vodak DT, Dobry DE, Kuehl PJ, Doyle-Eisele M, McDonald JD, Silcock A, et al. Platform formulation development utilizing a novel pulmonary excipient and in vivo evaluation of engineered particles of fluticasone propionate as a model formulation. Proc Resp Drug Deliv. 2009;2:251–4.
12. Kuehl PJ, Barrett EG, McDonald JD, Rudolph K, Vodak D, Dobry D, et al. Formulation development and in vivo evaluation of a new dry powder formulation of albuterol sulphate in beagle dogs. Pharm Res. 2010;27(5):894–904.
13. Cherrington AD, Neal DW, Edgerton DS, Glass D, Bowen L, Wilson W, et al. Inhalation of insulin in dogs: assessment of insulin levels and comparison to subcutaneous injection. Diabetes. 2004;53:877–81.
14. Edgerton DS, Neal DW, Scott M, Bowen L, Wilson W, Hobbs CH, et al. Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs. Diabetes. 2005;54:1164–70.
15. Edgerton DS, Stettler KM, Neal DW, Scott M, Bowen L, Wilson W, et al. Inhalation of human insulin is associated with improved insulin action compared with subcutaneous injection and endogenous secretion in dogs. J Pharmacol Exp Ther. 2006;319:1258–64.
16. Cote E. Clinical veterinary advisor, dogs and cats. Mosby: Elsevier; 2007.
17. Boer AH, Hagedoorn Pl, Schellekens RCA, Rottier BL, Bocca G, Duiverman EJ, Frijlink HW. Can systemic drug delivery via the pulmonary route be achieved effectively with a dry powder inhaler? Lessons Learned from Exubera. Proc Drug Deliv Lung. 2008;19.
18. Pikal MJ, Rigsbee DR. The stability of insulin in crystalline and amorphous solids: observation of greater stability for the amorphous form. Pharm Res. 1997;14(10):1379–87.
19. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56:588–99.
20. Breit J, Vodak DT, Kuehl PJ, Doyle-Eisele M, Reed MD, Schachtner B. Pharmacokinetic analysis of an inhalable spray-dried engineered particle formulation of camptothecin for the treatment of lung cancer. Proc Resp Drug Deliv. 2012;2:407–12.
21. Vodak DT, Dobry DE, Friesen D, Reed MD, Gigliotti AP, Kuehl PJ, et al. Dextran-based materials as excipients in engineered particle formulations: tailoring physical properties to optimize performance, manufacturability, and safety. Proc Resp Drug Deliv. 2011;2:1–9.
22. Sun WQ, Davidson P. Effect of dextran molecular weight on protein stabilization during freeze-drying and storage. Cryo Lett. 2001;22(5):285–92.